Moderna completes enrolment of phase 2 study of its mRNA vaccine against Covid-19
mRNA-1273 is Moderna’s second mRNA vaccine for an infectious disease to complete enrollment of a Phase 2 study, following the Company’s CMV Phase 2 study, which was fully